Number of participants with serious and non-serious adverse events 30 days [clinicaltrials_resource:37623e2fa479ccde8a62d3a6bb19725d]

Number of participants with serious and non-serious adverse events 30 days [clinicaltrials_resource:37623e2fa479ccde8a62d3a6bb19725d]

To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:37623e2fa479ccde8a62d3a6bb19725d
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant [clinicaltrials:NCT02065869]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number of participants with serious and non-serious adverse events 30 days [clinicaltrials_resource:37623e2fa479ccde8a62d3a6bb19725d]

To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:37623e2fa479ccde8a62d3a6bb19725d
Bio2RDF identifier
37623e2fa479ccde8a62d3a6bb19725d
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:37623e2fa479ccde8a62d3a6bb19725d
measure [clinicaltrials_vocabulary:measure]
Number of participants with serious and non-serious adverse events
time frame [clinicaltrials_vocabulary:time-frame]
description
To determine the maximum tolerated and/or recommended dose of BPX-501 cells.
identifier
clinicaltrials_resource:37623e2fa479ccde8a62d3a6bb19725d
title
Number of participants with serious and non-serious adverse events 30 days
@en
inDataset
type
label
Number of participants with se ...... 23e2fa479ccde8a62d3a6bb19725d]
@en